@GettyImages

Knowledge portal for inclusion of children in clinical trials

Introduction

The principle that children are not small adults remains the foundation for this resource: medicines developed for adults cannot simply be extrapolated to children because of well-recognized physiological, developmental and pharmacological differences between children and adults. For decades, studies of new drugs involving infants, children and adolescents have often been delayed relative to adults or never performed, resulting in a significant evidence gap that has left many effective treatments unlicensed or used off-label in paediatric practice. 

Closing this gap matters beyond childhood itself. A life-course approach recognizes that health in childhood shapes health in adulthood and that clinical development of children’s medicines is therefore an investment in the trajectory of a whole life. The development of medicine for children and adults should be seen as a continuum rather than as separate pathways. Connecting the two through streamlined, coordinated approaches, such as earlier and better-aligned paediatric planning, shared evidence generation and harmonized regulatory and study design, can reduce delays and duplication and ensure that safe, effective, age-appropriate treatments reach children when they need them and carry through into adult care. 

In May 2022, the World Health Assembly adopted resolution WHA75.8 to promote collaboration and equity in clinical trial practices by standardizing the inclusion of underrepresented populations, including children, to enhance their health outcomes and well-being. The inaugural WHO Global Clinical Trials Forum in November 2023 highlighted the urgency of including underrepresented groups in clinical research. In response to resolution WHA75.8, WHO published Guidance for best practices for clinical trials in 2024 and then a research agenda in 2025 to strengthen paediatric clinical trials and set research priorities to close critical gaps in research on child health (Box 1). 

Box 1. Critical gaps in paediatric research
  • Paediatric research remains disproportionately limited: only 10% of globally registered trials (2000–2023) included children, despite their substantial burden of preventable disease and mortality.
  • Major geographical and equity gaps persist: only 9% of paediatric trials were conducted in lower-middle-income countries and 1% in low-income countries, which have the greatest burden of childhood illness.
  • Evidence is particularly scarce for newborns and young infants: few trials focus specifically on the highest-risk period from birth through early infancy.
  • Critical evidence gaps remain for widely used interventions and priority conditions: including the safety and effectiveness of antibiotics and treatments for conditions such as sickle cell disease and childhood cancer.
  • Structural barriers constrain paediatric research: smaller markets, limited commercial incentives and ethical, regulatory and operational complexities.
  • Research priorities and investment are not sufficiently aligned with need: the disconnect between disease burden and research activity, especially in low-resource settings, underscores the need for targeted priority-setting, investment and high-quality trials to generate evidence that improves child survival, growth and development.
Source: The future of paediatric clinical trials – setting research priorities for child health: technical report. Geneva: World Health Organization; 2025 (iris.who.int/handle/10665/383291). Licence: CC BY-NC-SA 3.0 IGO.

The information in this knowledge portal was developed to address these gaps by providing practical guidance to support the design, implementation and oversight of clinical trials involving neonates, children and young people. It is intended as a living resource that draws on the latest international guidelines, regulatory frameworks and research literature and that will be updated as the field evolves.

Objectives


The objectives of this knowledge portal are: 

Research principles

To provide a structured overview of the ethical, regulatory and scientific principles underpinning paediatric clinical research

Practical guidance

To offer practical guidance on trial design, methodological approaches and implementation strategies specific to children

Community engagement

To promote meaningful patient and caregiver involvement in designing and conducting paediatric clinical trials

Trial support

To support trial investigators and clinical sites with implementation guidance specific to paediatric trials, including recruitment, informed consent, retention and sample collection

Resource access

To signpost readers to existing high-quality resources, guidelines, training courses and toolkits from international organizations and regulatory bodies

Disease specific guidance

To provide disease-specific guidance for common therapeutic areas in paediatric trials

Knowledge portal components


Abbreviations

COVID-19 coronavirus disease 2019

EMA European Medicines Agency

EU European Union

GAP-f Global Accelerator for Paediatric Formulations

ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials (Network)

SPIRIT Standard Protocol Items: Recommendations for Interventional Trials

Show less Show more

Disclaimers

Study materials and links to other websites are provided for your convenience, and this does not indicate that WHO endorses these materials or sites. WHO accepts no responsibility for the validity or accuracy of their content. The mention of specific companies or of certain manufacturers’ products does not imply WHO endorses or recommends them in preference to others of a similar nature that are not mentioned.

All external experts submitted to WHO a declaration of interest disclosing potential conflicts of interest that might affect, or might reasonably be perceived to affect, their objectivity and independence in relation to the subject matter of this guidance. WHO reviewed each of the declarations and concluded that none could give rise to a potential or reasonably perceived conflict of interest related to the subjects discussed at the meeting or covered by the guidance.

Artificial intelligence tools were used to support the development of this resource, including for organizing the content, drafting, editing and synthesizing information. The resource development team and subject-matter experts reviewed all content assisted by artificial intelligence. The development team is responsible for the final content and for ensuring that the information presented is accurate, relevant and appropriate for its intended use. Artificial intelligence tools were used to support the development process and do not replace expert review, scientific judgement or responsibility for the content.

Show less Show more

Acknowledgements

WHO gratefully acknowledges the contributions of many individuals and partner organizations to developing this knowledge portal.

The development of the technical content was initiated, coordinated and developed by Kristen Stolka, (Clinical Research Coordinator, Global Accelerator for Paediatric Formulations (GAP-f), Department of Science for Health, WHO headquarters), with technical contributions provided by WHO staff members: Per Ashorn, Yasir Bin Nisar and Wilson Were (Department of Sexual, Reproductive, Maternal, Child and Adolescent Health & Ageing, WHO headquarters), Martina Penazzato (GAP-f, Department of Science for Health, WHO headquarters), Djamila Reis (Regulation and Safety, Department of Regulation and Prequalification, WHO headquarters), Erin Sparrow (Department of Immunization, Vaccines & Biologicals) and Wei Zhang (Department of Science for Health, WHO headquarters). The following people provided substantial technical contributions, review and revisions: Adrie Bekker (Stellenbosch University, South Africa), Jeannie Collins (University College London, United Kingdom of Great Britain and Northern Ireland), Tim R. Cressey (Chiang Mai University, Thailand), Sally Ellis (Global Antibiotic Research and Development Partnership, Switzerland), Begonya Nafria Escalera (Hospital Sant Joan de Déu, Spain), Diana Gibb (University College London, United Kingdom of Great Britain and Northern Ireland), Theodore Ruel (University of California, San Francisco, United States of America), Smita Salunke and Jenny Walsh (European Paediatric Formulation Initiative, London, United Kingdom of Great Britain and Northern Ireland) and Mark Turner (Conect 4 Children Stichting, Kingdom of the Netherlands).

In addition, WHO sincerely thanks all members of the Clinical Research Working Group of GAP-f for their ongoing guidance and inputs to this resource, a key product of the Clinical Research Working Group: Maggie Abbassi (Cairo University, Egypt), Elaine Abrams and George Siberry (ICAP Global Health at Columbia University, USA), Fabiana Alves, Vincent Billoet, Janice Lee and Stephen Robinson (Drugs for Neglected Diseases Initiative, Switzerland), Alasdair Bamford, Diana Gibb, Ali Judd and Anna Turkova (University College London, United Kingdom of Great Britain and Northern Ireland), Julia Bielicki (University Children’s Hospital Basel, Switzerland), Daniele Dona, Carlo Giaquinto, Marc Lallemant and Pablo Rojo (Penta Foundation), Manal El-Sayed (Ain Shams University, Egypt), Ricardo Fernandes (Conect 4 Children Stichting, Kingdom of the Netherlands), Jane Fisher and Amanda Handley (Medicines Development for Global Health, Australia), Lisa Jane Frigati (University of Cape Town, South Africa), Anthony Garcia-Prats (University of Wisconsin, Madison, USA), Justin Green (Global Antibiotic Research and Development Partnership, Switzerland), Anneke Hesseling (Stellenbosch University, Cape Town, South Africa), Adeodata Kekitiinwa (Baylor University, Uganda), Shelly Malhotra (International AIDS Vaccine Initiative, USA), Anne Claire Marrast (Medicines for Malaria Ventures), Sharon Nachman (Stony Brook University, USA), Cécile Ollivier (Critical Path Institute, Kingdom of the Netherlands), Jennifer Pauley (St. Jude's Clinical Research Hospital, USA), Rob Pieters, Gilles Vassal and Susanne Wollaert (International Society of Paediatric Oncology, Switzerland), Thanyawee Puthanakit (Chulalongkorn University, Thailand) and Priscilla Tsondai (International AIDS Society).

Show less Show more